Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...

Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...

Dr. Micheal Ge, CEO of Kelun-Biotech said, "We are pleased to have entered into a partnership with Windward Bio for the SKB378/HBM9378, one of our pioneering pipelines in immunology area ...

Under the terms of the agreement, Windward Bio is granted an exclusive license to research, develop, manufacture, and commercialize HBM9378/SKB378 globally, excluding Greater China and several ...

HBM9378/SKB378 is designed to inhibit the TSLP-mediated signaling pathway, aiming to reduce airway inflammation and improve lung function in patients with COPD. "This regulatory clearance from the ...

Subject to the terms and conditions of the License Agreement, Windward Bio is granted an exclusive license for the research, development, manufacturing and commercialization of SKB378/HBM9378 ...

"We are delighted to partner with Windward Bio to advance the development of HBM9378/SKB378, a promising TSLP-targeted fully human antibody with significant potential to address immunological diseases ...

Under the terms of the agreement, Windward Bio is granted an exclusive license to research, develop, manufacture, and commercialize HBM9378/SKB378 globally, excluding Greater China and several ...